UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response

Lung cancer (Amsterdam, Netherlands), 2019-08, Vol.134, p.79-84

2019

Volltextzugriff (PDF)

Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network

BMC pulmonary medicine, 2019-11, Vol.19 (1), p.195-195, Article 195

2019

Volltextzugriff (PDF)

Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations

Cancers, 2024-04, Vol.16 (7), p.1249

2024

Volltextzugriff (PDF)

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study

International journal of molecular sciences, 2023-01, Vol.24 (2), p.1746

2023

Volltextzugriff (PDF)

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

Frontiers in oncology, 2023-05, Vol.13, p.1163768-1163768

2023

Volltextzugriff (PDF)

Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis

Therapeutic advances in medical oncology, 2024, Vol.16, p.17588359241272957

2024

Volltextzugriff (PDF)

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

NPJ precision oncology, 2020-06, Vol.4 (1), p.15-15, Article 15

2020

Volltextzugriff (PDF)

117 Prognostic factors for 90-day acute care outcomes in lung cancer patients 70 and over

Lung cancer (Amsterdam, Netherlands), 2024-04, Vol.190, p.107678, Article 107678

2024

Volltextzugriff (PDF)

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR -mutated resectable non-small-cell lung cancer: NeoADAURA

Future oncology (London, England), 2021-11, Vol.17 (31), p.4045-4055

2021

Volltextzugriff (PDF)

128 90 day admissions and mortality in lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2024-04, Vol.190, p.107689, Article 107689

2024

Volltextzugriff (PDF)

39 - Patient characteristics and treatment patterns in resectable early-stage NSCLC: UK subgroup analysis of a global real-world study

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S17-S17

2023

Volltextzugriff (PDF)

Patient characteristics and treatment patterns in resectable early-stage NSCLC: UK subgroup analysis of a global real-world study

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S17

2023

Volltextzugriff (PDF)

DO GENOMIC ALTERATIONS INflUENCE THE DEVELOPMENT OF BRAIN METASTASES IN ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER? A SYSTEMATIC REVIEW AND META-ANALYSIS

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_3), p.iii6-iii7

2023

Volltextzugriff (PDF)

Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis

Journal of thoracic oncology, 2023-12, Vol.18 (12), p.1703-1713

2023

Volltextzugriff (PDF)

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)

Lung cancer (Amsterdam, Netherlands), 2021-12, Vol.162, p.9-15

2021

Volltextzugriff (PDF)

Diverse epigenetic strategies interact to control epidermal differentiation

Nature cell biology, 2012-07, Vol.14 (7), p.753-763

2012

Volltextzugriff (PDF)

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

International immunopharmacology, 2022-09, Vol.110, p.108985-108985, Article 108985

2022

Volltextzugriff (PDF)

76 - Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S33-S33

2023

Volltextzugriff (PDF)

Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.S33

2023

Volltextzugriff (PDF)

Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.S41

2022

Volltextzugriff (PDF)

87 - Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer

Lung cancer (Amsterdam, Netherlands), 2022-03, Vol.165, p.S41-S41

2022

Volltextzugriff (PDF)

Role and evidence for targeted therapies in surgically resectable non-small cell lung cancer: a narrative review

Video-Assisted Thoracic Surgery, 2022-06, Vol.7, p.11-11

Escriu, Carles

2022

Volltextzugriff (PDF)

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer

Oncogene, 2019-02, Vol.38 (7), p.1136-1150

2019

Volltextzugriff (PDF)

Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer

Journal of thoracic disease, 2016-09, Vol.8 (9), p.2357-2359

2016

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(9)
Oncology
(9)
Lung Cancer
(8)
Chemotherapy
(5)
Lung Neoplasms - Drug Therapy
(5)
Respiratory System
(5)
Tumors
(5)
Cancer Therapies
(4)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)
Carcinoma, Non-Small-Cell Lung - Genetics
(4)
Care And Treatment
(4)
Female
(4)
Immunotherapy
(4)
Lung Neoplasms - Genetics
(4)
Male
(4)
Metastasis
(4)
Middle Aged
(4)
Mutation
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Lung Cancer
(10)
Npj Precision Oncology
(2)
Bmc Cancer
(1)
Bmc Pulmonary Medicine
(1)
Cancer Research
(1)
Cancers
(1)
Frontiers In Oncology
(1)
Future Oncology
(1)
International Immunopharmacology
(1)
International Journal Of Molecular Sciences
(1)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response

Treatment beyond four cycles of first line Platinum and Etoposide chemotherapy in real-life patients with stage IV Small Cell Lung Cancer: a retrospective study of the Merseyside and Cheshire Cancer network

Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations

The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

117 Prognostic factors for 90-day acute care outcomes in lung cancer patients 70 and over

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR -mutated resectable non-small-cell lung cancer: NeoADAURA

128 90 day admissions and mortality in lung cancer patients

39 - Patient characteristics and treatment patterns in resectable early-stage NSCLC: UK subgroup analysis of a global real-world study

Patient characteristics and treatment patterns in resectable early-stage NSCLC: UK subgroup analysis of a global real-world study

DO GENOMIC ALTERATIONS INflUENCE THE DEVELOPMENT OF BRAIN METASTASES IN ADVANCED AND METASTATIC NON-SMALL CELL LUNG CANCER? A SYSTEMATIC REVIEW AND META-ANALYSIS

Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis

Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)

Diverse epigenetic strategies interact to control epidermal differentiation

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

76 - Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Immunotherapy-related adverse events (irAEs) in real world patients with advanced non-small cell lung cancer (aNSCLC) on chemoimmunotherapy: a Spinnaker study sub-analysis

Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer

87 - Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer

Role and evidence for targeted therapies in surgically resectable non-small cell lung cancer: a narrative review

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer

Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer

Suchergebnisse filtern